IGF-1 DES 1mg/vial 1 Vial by Knoll Pharmaceuticals

Usage

1. Reconstitute with bacteriostatic water: Draw 1–2 mL of bacteriostatic water and inject slowly along the vial wall — never shake; swirl gently until the lyophilised powder dissolves completely into a clear solution.
2. Calculate your working dose: Using the final volume (e.g., 2 mL per 1 mg vial = 0.1 mL per 50 mcg), mark the insulin syringe at the correct graduation before drawing.
3. Select the injection site aligned with your hyperplasia goal: For satellite-cell stimulation in a target muscle group, intramuscular injection into the trained muscle is standard practice in research and bodybuilding literature.
4. Time the injection relative to nutrient availability: To leverage the partitioning effect, administer within 30 minutes post-training, coinciding with carbohydrate intake to maximise GLUT4-driven glucose uptake into muscle glycogen.
5. Rotate injection sites: Repeated dosing in the same location risks localised tissue irritation; systematic rotation across injection points maintains tissue quality.
6. Store reconstituted vials correctly: Keep in a refrigerator at 2–8 °C and use within 21–28 days; discard if the solution appears cloudy, discoloured, or contains visible particulates.

Warnings

Frequently asked questions

How does IGF-1 DES differ from standard endogenous IGF-1 in terms of receptor binding?

IGF-1 DES lacks the first three N-terminal amino acids of native IGF-1, which dramatically reduces its affinity for insulin-like growth factor binding proteins (IGFBPs). Because IGFBPs normally sequester a large fraction of circulating IGF-1, the DES variant maintains a higher free-peptide fraction available for direct IGF-1 receptor activation, making it more potent on a molar basis at the tissue level than unmodified IGF-1.

What exactly is muscle hyperplasia and how does IGF-1 DES contribute to it?

Muscle hyperplasia is the increase in the total number of muscle fibres, distinct from hypertrophy, which enlarges existing fibres. IGF-1 DES stimulates quiescent satellite cells — the resident stem cells of skeletal muscle — to proliferate and differentiate into new myoblasts via IGF-1R activation and downstream PI3K/Akt signalling. Over a sustained cycle, this satellite-cell recruitment can theoretically establish a greater structural base for subsequent hypertrophic growth.

When is the optimal time to inject IGF-1 DES to maximise nutrient partitioning benefits?

Nutrient partitioning benefits are maximised when IGF-1 DES is administered within approximately 30 minutes following resistance training, timed to coincide with carbohydrate consumption. At this window, GLUT4 translocation induced by both exercise and IGF-1R/PI3K/Akt activation is additive, driving circulating glucose preferentially into muscle glycogen stores rather than adipose tissue — supporting a lean-mass favourable environment during the anabolic recovery period.

How should the Knoll Pharmaceuticals IGF-1 DES 1mg vial be reconstituted and stored after opening?

Add 1–2 mL of bacteriostatic water by injecting slowly along the inner vial wall, then swirl gently — never vortex or shake — until the lyophilised powder dissolves fully into a clear solution. Store the reconstituted vial refrigerated at 2–8 °C and use within 21–28 days. Discard immediately if the solution becomes cloudy, changes colour, or develops visible particulate matter.

What syringe type and graduation should be used for accurate micro-dosing of IGF-1 DES?

A 29–31 gauge insulin syringe (0.3 mL or 0.5 mL barrel) is standard for IGF-1 DES administration, providing the fine graduations needed to measure doses in the 20–100 mcg range accurately. After reconstituting 1 mg in 2 mL of bacteriostatic water, each 0.1 mL equals 50 mcg — a straightforward ratio that makes dosing calculations on an insulin syringe reliable and repeatable across multiple administrations from one vial. (2) angle_used

Manufacturer

Knoll Pharmaceuticals routes its IGF-1 DES 1 mg/vial line through a sequentially ordered, two-checkpoint quality-release architecture whose stages address entirely separate analytical risk categories — one checkpoint cannot substitute for the other, and a failing result at either stage disqualifies the entire batch. The first stage is HPLC (High-Performance Liquid Chromatography) characterisation of the bulk IGF-1 DES active pharmaceutical ingredient: the chromatographic trace generated by each batch is compared against a certified reference standard specific to the truncated peptide sequence, simultaneously confirming molecular identity and quantifying purity; batches whose profiles deviate from the acceptance specification are rejected before fill-and-finish operations begin. The second stage is a LAL (Limulus Amebocyte Lysate) endotoxin assay conducted on finished, filled vials: this test leverages the coagulation cascade of horseshoe-crab amoebocytes to detect and quantify bacterial lipopolysaccharide contamination at sub-threshold limits consistent with injectable peptide standards, ensuring that the sterile-filtration and lyophilisation steps have not introduced endotoxin burden. Only vials that clear both the HPLC purity gate and the LAL endotoxin gate are released for distribution — a verification structure that supports the batch-level traceability and purity confidence underlying the product's HPLC-Verified badge.